BioNTech (BNTX) Q3 2026 earnings summary

Executive summary

• 2026 strategic progress centered on late-stage oncology, tumor-focused development and combination therapies; six Phase III trials initiated during the year.

• Pipeline and partnership breadth, alongside €16.2B in cash equivalents and security investments, support the ambition to become a diversified multi-product business by 2030.

Financial highlights

• Q3 2026 revenue was €1,289.2M versus €1,518.9M YoY, primarily reflecting lower COVID-19 vaccine demand; €613M came from the BMS pumitamig partnership.

• Q3 IFRS operating profit was €125.0M versus a €46.9M loss; IFRS net profit was €184.5M and adjusted net profit €440.9M.

• 9M 2026 revenue was €1,512.9M versus €1,962.5M; adjusted net loss was €615.9M versus €27.1M.

• Q3 adjusted R&D was €578.5M versus €479M; IFRS R&D was €748.1M, including €169.6M in impairment adjustments. Q3 SG&A was €178.5M versus €148.5M.

• 9M adjusted R&D was €1,583M versus €1,514M; SG&A was €527.1M versus €406.5M.

Outlook and guidance

• FY 2026 revenue guidance increased to €1.7B–€1.9B from €1.6B–€1.9B; adjusted R&D guidance is €2.0B–€2.3B and adjusted SG&A guidance €700M–€800M.

• Seven global pivotal pumitamig studies are expected to be ongoing by year-end; event-driven trial timing and completion dates may change as data mature.

• Gotistobart’s first pivotal-trial interim analysis is expected in 2026, subject to event accrual projections and IDMC review; a second analysis is planned next year.

• First pivotal pumitamig combinations informed by signal-seeking data are expected to begin in 2027; 2027 financial plans remain in development.